Onconova Therapeutics (ONTX) Gets a Buy Rating from Noble Financial

By Ryan Adsit

In a report issued on October 25, Ahu Demir from Noble Financial maintained a Buy rating on Onconova Therapeutics (ONTXResearch Report), with a price target of $12.00. The company’s shares closed last Monday at $0.68, close to its 52-week low of $0.65.

According to TipRanks.com, Demir is a 3-star analyst with an average return of 3.6% and a 46.2% success rate. Demir covers the Healthcare sector, focusing on stocks such as Dyadic International, Electrocore Llc, and TherapeuticsMD.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Onconova Therapeutics with a $15.00 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $6.05 and a one-year low of $0.65. Currently, Onconova Therapeutics has an average volume of 315.2K.

Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ONTX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer.